Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
Zimmer Biomet Holdings, Inc. filed this Current Report on Form 8-K on July 28, 2016, to report its results of operations for the quarter ended June 30, 2016. The filing incorporates by reference an earnings release (Exhibit 99.1) containing detailed financial data.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached earnings release (Exhibit 99.1) and are not explicitly stated in the body of this Form 8-K.
The company reports financial results using both GAAP and non-GAAP measures. Non-GAAP metrics include:
- Adjusted Net Earnings and Adjusted Diluted EPS: Exclude inventory step-up, manufacturing charges, certain claims, special items, intangible asset amortization, and merger-related expenses.
- Sales Growth: Presented on GAAP, pro forma, and adjusted pro forma constant currency bases.
- Pro Forma Revenue: Adjusted to reflect the inclusion of Biomet revenue on a GAAP basis.
- Adjusted Pro Forma Revenue: Further adjusted for divestiture remedies.
Material Changes and Management Commentary
Management utilizes non-GAAP measures to evaluate ongoing operating performance, identify trends masked by one-time items, and facilitate period-to-period comparisons. These metrics are also used in incentive compensation programs. The filing notes that special items include expenses from business combinations, global restructuring, quality initiatives, employee termination benefits, and asset impairments.
Projected revenue growth information is presented on GAAP, adjusted pro forma, and adjusted pro forma constant currency bases. The filing does not detail specific year-over-year percentage changes or material variances in the text provided.
Risks and Contingencies
The filing includes standard disclosures regarding non-GAAP financial measures, stating they may not be comparable to similar measures reported by other companies and should not be viewed as a substitute for GAAP measures. Reconciliations to GAAP measures are included in the attached earnings release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and EPS figures for the quarter ended June 30, 2016.
- Verify the reconciliation between non-GAAP adjusted earnings and GAAP net earnings to understand the impact of merger-related charges and restructuring costs.
- Examine the "adjusted pro forma constant currency" sales growth figures to assess organic performance excluding currency fluctuations and divestiture impacts.
- Confirm the specific components of "special items" and "other certain tax adjustments" detailed in the earnings release.